mitiglinide

Also known as Mitiglinide calcium hydrate, KAD-1229

Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.

Research

163 papers

Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus.The Annals of pharmacotherapy · 2010
Mitiglinide for type 2 diabetes treatment.Expert opinion on pharmacotherapy · 2013
Mitiglinide: KAD 1229, S 21403.Drugs in R&D · 2004
Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients.Expert opinion on pharmacotherapy · 2008
[Mitiglinide (KAD-1229)].Nihon rinsho. Japanese journal of clinical medicine · 2002

via PubMed

Wikidata facts

Mass: 315.183444

Show 4 more facts

chemical formula: C₁₉H₂₅NO₃
isomeric SMILES: C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)O
canonical SMILES: C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)O
defined daily dose: 30

Sources (4)

via Wikidata · CC0

~1 min read

Article

4 sections

Contents

Pharmacology
Dosage
References
External links

Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.

Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.